Drug Cards4

8/6/2019 Drug Cards4

1/7

Med Name:

Docusate (calcium or

sodium)

Classification:

Therapeutic: laxative,emollient; stool softener

Usual Adult Dose:

PO 50-300 mg daily (sodium)or 240mg (calcium or

potassium) prn; enema 4 ml

Mechanism of Action:

Increases water, fatpenetration in intestine,

allows for easier passageof stool

Purpose/Expected Action

for Your Patient:

Dosage:

Route:

Times of Administration:

Priority Med Specific Patient Teaching

1. Take with a full glass of water unless on fluidrestrictions and increase fluid intake.2.Notify prescriber if constipation unrelieved or ifsymptoms of electrolyte imbalance occur: musclecramps, pain, weakness, dizziness, excessive thirst

Lab work you will monitor:

Electrolyte levels

Priority Med Specific Nursing Assessment

1. Assess cause of constipation, identify whether fluids,bulk or exercise are missing from lifestyle, constipatingdrugs2. Discontinue drug if cramping, rectal bleeding,nausea, vomiting occur

Med Name:

Morphine Sulfate

injection

Classification:

Therapeutic: opioid

analgesic

Pharmacologic: opioid

agonist

Usual Adult Dose:

4-10 mg every 3-4 hours.


Morphine is an opioid. It

acts upon specific

receptors in the brain and

spinal cord to decrease

the feeling of pain and to

reduce the emotional

response to pain.


for Your Patient:

Dosage: 4mg/1ml IV

push (Slow) 1min w/ NS

dilute

Route: IV Push

Times of Administration:Q 3 hours PRN


1. Instruct pt. how and when to ask for pain medication

2. Over medication, sedation, and respiratorydepression can result

3. Caution pt. to call for assistance when ambulating

due to drowsiness

4. Advise pt. to change position slowly to minimize

orthostatic hypotension

Lab work you will monitor

1. Plasma amylase or lipase levels

Priority Med Specific Nursing Assessment1. Assess type, location, and intensity of pain prior to and one

hour following administration.

2. Assess level of consciousness, BP, pulse, and respirationsbefore and during administration.

3. Assess bowel function routinely, institute prevention of


2/7

constipation w/ increased intake of fluids and laxatives.

Med Name:

Cefazolin

Classification:

Anti-infective

Third-generation

cephalosporins

Usual Adult Dose:

200 mg q12h


Binds to bacterial cell

wall causing cell death


for Your Patient:

Dosage: 1GM/D5W 50 ml

duplex INJ

Route: IVPB


1400

Priority Med Specific Patient Teaching:

1. Notify health care provider if fever and diarrhea

develop

2. Signs of infection

Lab work you will monitor:

1. CBC

2. BUN and creatinine

Priority Med Specific Nursing Assessment:

1. Assess for signs of anaphylaxis(rash, pruritus,

laryngeal edema, wheezing)

2. Monitor bowel function

Med Name:

Ondansetron

Classification:

Antiemetic

Usual Adult

Dose:

.15mg/kg in 3

doses


Antagonist used for the prevention of chemotherapy-induced nausea and vomiting


for Your Patient:

To reduce nausea and vomiting

Dosage:

4mg/ 2mg solution

Route:

IV Push

Times of

Administration:

PRN


1. Teach that drug is used to prevent N&V2. Report any rash, Diarrhea, constipation,

altered respirations


1.AST

2.ALT


1. Assess for dehydration

2. Monitor electrolyte imbalance w/


3/7

diarrhea/N&V

Med Name:

Acetominophen/

Oxycodone

Classification:

Therapeutic: opioidanalgesic

Pharmacological: opioidagonist

Usual Adult Dose:

5-10mg q 3-4 hr prn/325-500mg combination dose


Binds to opiate receptors

in the CNS. Alters theperception of and responseto painful stimuli, while

producing generalizedCNS depression.


for Your Patient:

Patient will havedecreased pain and a painlevel < 3.

Dosage: 5mg PRN

Route: PO


2 tabs q 4 hrs


1. may cause drowsiness or dizziness

2. change positions slowly since it can cause orthostatichypotension


1. plasma lipase

2. plasma amylase


1. BP, P and RR before and during therapy

2. type, location and intensity of pain prior toadministration and one hour afterwards to determine

effectiveness


4/7

Med Name:

Calcium Citrate

Classification:mineral and electrolyte

replacements/ supplements

Usual Adult Dose:PO:

tx of depletion, osteoporosis-1-2g/day

IV: 2.25-14 mEq depending

on problem


Used by skeletal, muscular,

and nervous systems.

Permeability maintainance of

cell membrane and

capillaries. Activates nerve

impulses in muscle. Needed

in formation of bones and

coagulation. Replaces Ca in

deficiency states and controlshyperphosphatemia in end

stage renal disease.


for Your Patient:

Calcium depletion

supplementation

Dosage: 950 mg BID

Route: PO


1000


1. Teach pt not to take with foods containing large amountsof oxalic acid, phytic acid, or phosphorus. (spinach, cereals,

milk or dairy)

2. Teach pts to avoid excess use of tobacco or alcoholproducts.


1. serum calcium or ionized calcium chloride, Na, K,

magnesium, albumin, PTH for hypocalcemia pt2. monitor phosphate levels if kidney pt.


1. monitor BP, pulse, and ECG throughout parenteral therapyfor hypotention, bradycardia, arrhythmias, cardiac arrest

2.monitor pt for hypocalcemia (paresthesia, muscletwitching, , laryngospasms, colic, cardiac arrhythmias,

Chvosteks or Trousseaus sign)


5/7

Med Name:

Ferrous Gluconate

Classification:

Hematinics

Usual Adult Dose:

750-1500 mg/day (1-3

doses per day)


Delivers the necessary

iron content for oxygen

binding and the

formation of hemoglobin


for Your Patient:

IRON and RBC

production

Dosage: 325 mg QD

Route: PO


1000


5. Teach pt to refrain from ingesting dairy,caffeine or foods containing ascorbic acid such

as oranges and tomatoes due to its

pharmakinetic changes to the absorption rate

of the drugs.

6. Take with food (GI irritation), and notify them

that iron may cause dark green or blackdiscoloration to stool.


2. Hemoglobin

3. Reticulocyte Count


4. Monitor bowel movements due to its common

side effect of constipation

5. I/O and daily wt

Med Name:

Sennosides

(Ex-Lax)

Classification:

Therapeutic: laxatives

Pharmacologic: stimulantlaxatives

Usual Adult Dose:12-50 mg 1-2 times daily

Larger doses have beenused to treat/preventopioid-induced

constipation.


Alter water and electrolytetransport in the largeintestine, resulting inaccumulation of water and

increased peristalsis.


for Your Patient:

for constipation control

Dosage: 8.6 mg BID

Route: PO


1000


1. Take with full glass of water

2. Encourage mobility, fluid/fiber, and others ways to promotehealthy bowel function.

3. Patient with cardiac disease should avoid straining when voiding.


1. ElectrolytesPriority Med Specific Nursing Assessment

1. Assess patient for abdominal distension, presence of bowelsounds, and usual pattern of bowel function

2. Assess color, consistency and amount of stool produced.


6/7

Med Name:

Vitamin D

Classification:

Vitamin Supplements

Usual Adult Dose:

600 IU

(15 mcg)


Vitamin D promotescalcium absorption in the

gut and maintains adequateserum calcium and

phosphate concentrationsto enable normal

mineralization of bone and

to prevent hypocalcemictetany. It is also needed for

bone growth and boneremodeling by osteoblastsand osteoclasts [1,2].


for Your Patient:

for adequate Calcium

absorption

Dosage: 600 IU TID

Route:po


1000


Teach pt the importance of taking with foods for

adequate absorption due to being a fat soluble

vitamin


Serum electrolytes

CBC


Dietary status and I/O

Med Name:

Amlodipine/Norvasc

Classification:

Therapeutic -AntihypertensivesPharmacologic - CalciumChannel Blockers

Usual Adult Dose:

5-10mg once daily


Inhibits calcium fromgoing into myocardial andsmooth vascular smoothmuscle cells, inhibitingexcitation-contractioncoupling; manage bp and

angina


for Your Patient:

Decrease and maintain

stabilized blood pressure

Dosage: 10 mg

Route: PO


1000


1. Caution pt to change positions slowly tominimize orthostatic hypotension

2. May cause drowsiness or dizziness


1. None


1. Monitor bp and pulse before and during therapy2. Monitor intake and output ratios and daily

weight
http://ods.od.nih.gov/factsheets/vitamind/#en1%23en1http://ods.od.nih.gov/factsheets/vitamind/#en1%23en1http://ods.od.nih.gov/factsheets/vitamind/#en2%23en2http://ods.od.nih.gov/factsheets/vitamind/#en2%23en2http://ods.od.nih.gov/factsheets/vitamind/#en1%23en1


7/7

Documents

Drug Cards4